Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Shaji Kumar, ASH 2020 – Highlights from ASH 2020

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 7th 2021

It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress.

The abstracts ‘Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma‘ (ABSTRACT NUMBER: 179) and ‘Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma‘ (ABSTRACT NUMBER: 133) were presented at the virtual 62nd ASH Annual Meeting and Exposition, 5-8 December, 2020.

Questions

  1. Please could you give an overview of MEDI2228 and its mechanism of action? (0:07)
  2. What have the findings of the first-in human study taught us about the efficacy and safety of MEDI2228 in patients with relapsed/refractory multiple myeloma? (1:08)
  3. What is the rationale for the use of anti-BCMA CAR-T cells in the treatment of patients with relapsed/refractory multiple myeloma? (3:33)
  4. On the basis of data from Lummicar-2, how does CT053 CAR-T cell therapy compare with other CAR-T cell therapies in development for multiple myeloma? (4:46)
  5. What were your personal highlights of this year’s ASH virtual congress? (6:53)

Speaker Disclosures: Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio; Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca, and (with personal payment) Oncopeptides, Beigene and Antagene.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of ASH 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup